ClinicalTrials.gg

Program

obeldesivir

Also written as “Obeldesivir”.

Its studies are mostly in COVID-19 · Respiratory Syncytial Virus Infections, led by Gilead Sciences.

Furthest: phase 3, since Oct 31, 20226 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences60 open or runningphase 3since Oct 31, 2022Oct 31, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2022First study: phase 3 study in COVID-19First studyNCT05603143 · 468 enrolled · Brazil, Bulgaria, Canada and more
  2. Feb 3, 2023Phase 3 study in COVID-19NCT05715528 · 2,011 enrolled · United States, Japan
  3. Aug 14, 2023Phase 3 study in COVID-19NCT05996744 · 3 enrolled · United States
  4. Sep 3, 2024Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06585150 · 150 enrolled · United States
  5. Nov 7, 2024Phase 2 study in Filovirus DiseaseNCT06682234
  6. Jan 15, 2025Phase 2 study in Respiratory Syncytial Virus InfectionsNCT06784973 · 4 enrolled · United States, Japan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06784973Respiratory Syncytial Virus Infections · United States, Japan2TerminatedApr 16, 20254
NCT06682234Filovirus Disease2WithdrawnDec 20250
NCT06585150Respiratory Syncytial Virus Infections · United States2TerminatedMay 8, 2025150
NCT05996744COVID-19 · United States3TerminatedFeb 23, 20243
NCT05715528COVID-19 · United States, Japan3CompletedNov 28, 20232,011
NCT05603143COVID-19 · Brazil, Bulgaria, Canada and more3TerminatedNov 7, 2023468

How it is read

Names in the registry

  • “Obeldesivir”, 5 entries
  • “obeldesivir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.